Medigene extends cancer immunotherapy alliance with bluebird bio
Category: #health  By Saipriya Iyer  Date: 2018-05-16
  • share
  • Twitter
  • Facebook
  • LinkedIn

Medigene extends cancer immunotherapy alliance with bluebird bio

Medigene AG, a Germany-based biotech firm, and bluebird bio Inc., have reportedly decided to extend their collaboration over cancer immunotherapy. The strategic move may plausibly be aimed at producing a revenue of over USD 509 million for Medigene.

Reportedly, both the firms have decided to increase the number of target antigens/major histocompatibility complex restriction combinations from four to six for the discovery of particular TCR lead candidates. Sources also claimed that the partnership is targeted toward the development of two more TCR-T cancer treatments.

Celgene Corporation, a U.S. based biotech firm, has agreed to shell out a one-time installment of USD 8 million to Medigene. It has been speculated that Celgene will pay nearly up to USD 250 million in terms of milestone payments for two novel TCR ventures. As per reliable sources, Celgene Corp. is also expected to pay double-digit tiered royalties on the net sales of these successful TCR programs.

If reports are to be relied on, the deal between Medigen & bluebird bio Inc., which was estimated at over USD 1 billion in 2016, will help in the integration of Medigen’s TCR isolation & characterization platform with bluebird bio’s manufacturing, lentiviral vector, synthetic biology, and gene-editing proficiencies. Experts familiar with the matter have claimed that TCR tool developed by Medigene AG has been designed to alter T-cells of the cancer patient with tumor-specific TCRs, thereby generating cells that would be able to aptly identify and destroy cancer tumor cells.

As per the terms & conditions stated in the agreement, bluebird bio has taken the responsibility for preclinical as well as clinical growth & commercialization of TCR-T candidates. In return, the company is likely to acquire a license for the specific TCRs patents. Some of the key officials of Medigene have stated that EBITDA guidance, revenue, and R&D funding will remain unaltered though the agreement is extended.



About Author

Saipriya Iyer

Email: [email protected]   

Saipriya Iyer

Saipriya Iyer develops content for Market Size Forecasters, Algosonline, and myriad other platforms. A computer engineer by profession, she ventured into the field of writing for the love of playing with words. Having had a previous experience of 3 years under her bel...

Read More

More News By Saipriya Iyer

CTI-Medidata partner to adopt Remote Source Review in clinical trials
CTI-Medidata partner to adopt Remote Source Review in clinical trials
By Saipriya Iyer

CTI Clinical Trial and Consulting Services will reportedly adopt Remote Source Review of Medidata. Medidata is the end-to-end solutions provider to support the clinical trials. This contract research organization will ...

NIMS begins subject enrollment for Phase 1 trial of COVID-19 vaccine
NIMS begins subject enrollment for Phase 1 trial of COVID-19 vaccine
By Saipriya Iyer

Nizam’s Institute of Medical Science (NIMS) has recently commenced the enrollment of subjects for its Phase 1 clinical trials of the COVID-19 vaccine. It is the 1st indigenous coronavirus vaccine candidate develo...

Walmart to compete Amazon Prime with new subscription service, Walmart
Walmart to compete Amazon Prime with new subscription service, Walmart
By Saipriya Iyer

U.S retail giant, Walmart Inc. has recently joined the race against Amazon with its latest subscription service, Walmart+. Similar to Amazon Prime, the new subscription service will endow Walmart customers wi...